Navigation Links
Panacea Pharmaceuticals, Inc. Presents Data That Its Cancer Biomarker HAAH is Readily Detectable in Serum Exosomes
Date:3/30/2017

GAITHERSBURG, Md., March 30, 2017 /PRNewswire/ -- Panacea Pharmaceuticals, Inc. presents a paper regarding detection of the cancer biomarker HAAH at the annual American Association for Cancer Research (AACR) meeting in Washington DC held April 1-5, 2017. The paper is titled:

"Improved Detection of Cancer Specific Serum Exosomal Aspartyl (Asparaginyl) beta Hydroxylase (HAAH)"

The paper demonstrates major refinements to Panacea's multi-cancer HAAH-exosome detection assay that targets the cancer-specific blood serum biomarker HAAH. The cancer field is intensely focused upon exosomes, which are small cell-like nanoparticles derived from the cancer cells that are proving to be important biomarkers and mediators of cancer cell metastasis and progression.

The association of Panacea's target molecule HAAH with exosomes has led to a better individual understanding of these biomarkers as well as further development of a markedly improved diagnostic test with higher sensitivity and specificity than previous versions of the assay.

"We are excited to report our continued advances in the understanding of the role of serum exosomes in the detection and monitoring of cancer," said Hossein Ghanbari, Ph.D., CEO and CSO of Panacea.

About Panacea Pharmaceuticals, Inc.

Panacea Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel biologically targeted cancer therapies and diagnostics for unmet medical needs and is headquartered in Gaithersburg, Md. The company has recently initiated a Phase 1 trial of its PAN-301-1 therapeutic cancer vaccine in prostate cancer patients and has late-nonclinical stage projects in serodiagnosis of cancer, immuno-imaging of cancer, monoclonal antibody-based immunotherapy of cancer and neuroprotection, specifically in prevention of chemotherapy-induced cognitive impairment and peripheral neuropathy.

Contact:  Steven Fuller, Panacea Pharmaeceuticals, Inc., 240-454-8010, sfuller@panaceapharma.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/panacea-pharmaceuticals-inc-presents-data-that-its-cancer-biomarker-haah-is-readily-detectable-in-serum-exosomes-300431997.html


'/>"/>
SOURCE Panacea Pharmaceuticals, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Goodwin Biotechnology was Selected by Panacea Pharmaceuticals for a Highly Specialized Vaccine Fill / Finish Project
2. Panacea Pharmaceuticals Engages Accelovance For Clinical Development Of Its Novel Nanoparticle-Based Therapeutic Cancer Vaccine
3. Panacea Pharmaceuticals Presents Three Papers Regarding Its Nanoparticle-Based Therapeutic Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting at National Harbor, MD
4. OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Year End 2016
5. Company Of Murdered California Urologist, Absorption Pharmaceuticals, Files Suit Against Multi-National Maker Of Everyday Household Products For Trade Secret Theft And Fraud
6. Provectus Biopharmaceuticals, Inc. Announces Extension of Rights Offering
7. Cornerstone Pharmaceuticals, Inc. Announces the Addition of World-Renowned Experts to Scientific and Medical Advisory Boards
8. Purcell Julie & Lefkowitz LLP Is Investigating HedgePath Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
9. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Anthera Pharmaceuticals, Inc. (ANTH)
10. Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
11. EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Alexion Pharmaceuticals, Inc. - ALXN
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2019)... ... August 19, 2019 , ... Like so many senior executives in complex industries, a ... he had to be able to talk about it. He turned a make-it-or-break-it opportunity ... uses for all types of speaking events. , On Monday, September 9, 2019 at ...
(Date:8/19/2019)... ... August 19, 2019 , ... The ... promote standards of excellence within the field of treatment for eating disorders, recommends ... communication with others who have a similar mission. , Founded in 1985, ...
(Date:8/16/2019)... ... August 16, 2019 , ... ... Movement Desensitization and Reprocessing therapy (EMDR). This therapeutic technique aims to reduce psychological ... used for post-traumatic stress disorder (PTSD), depression, chronic pain, anxiety, and grief. ...
Breaking Medicine Technology:
(Date:8/21/2019)... ... August 21, 2019 , ... Alsana ... in Huntsville, Ala. in early 2020. Alsana will offer an eating disorder treatment ... Outpatient Program (IOP). The integrative program will provide a continuum of care as ...
(Date:8/21/2019)... ... August 21, 2019 , ... Future ... July 28. The Phase II expansion of Providence Point in Pittsburgh’s Scott Township ... as construction of the 70-unit apartment tower, Hamilton Tower. , The ...
(Date:8/19/2019)... ... 2019 , ... Professional Enrollment Concepts (PEC), a top benefits ... have ranked #3056 on the 2019 Inc. 5000 Fastest-Growing Private Companies list. The ... most successful companies within the American economy's most dynamic segment—its independent small and ...
(Date:8/17/2019)... ... August 17, 2019 , ... ... America’s Fastest-Growing Private Companies—the Inc. 5000 , For the 2nd Year In a ... Revenue Growth of 192% Percent , Inc. magazine today revealed that YellowTelescope LLC ...
(Date:8/16/2019)... ... August 16, 2019 , ... Tim Stouffer, ICS ... Mid-Atlantic and North East at the 2019 Safety Academy sponsored through Associated Builders ... existing construction safety concepts and define not only a safety program but focus ...
Breaking Medicine News(10 mins):